JP2014527071A5 - - Google Patents

Download PDF

Info

Publication number
JP2014527071A5
JP2014527071A5 JP2014528610A JP2014528610A JP2014527071A5 JP 2014527071 A5 JP2014527071 A5 JP 2014527071A5 JP 2014528610 A JP2014528610 A JP 2014528610A JP 2014528610 A JP2014528610 A JP 2014528610A JP 2014527071 A5 JP2014527071 A5 JP 2014527071A5
Authority
JP
Japan
Prior art keywords
group
compound
agent
peg
stealth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014528610A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014527071A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/053197 external-priority patent/WO2013033438A2/en
Publication of JP2014527071A publication Critical patent/JP2014527071A/ja
Publication of JP2014527071A5 publication Critical patent/JP2014527071A5/ja
Pending legal-status Critical Current

Links

JP2014528610A 2011-08-31 2012-08-30 H−ホスホネートによるナノ粒子pegの改変 Pending JP2014527071A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161529694P 2011-08-31 2011-08-31
US61/529,694 2011-08-31
PCT/US2012/053197 WO2013033438A2 (en) 2011-08-31 2012-08-30 Nanoparticle peg modification with h-phosphonates

Publications (2)

Publication Number Publication Date
JP2014527071A JP2014527071A (ja) 2014-10-09
JP2014527071A5 true JP2014527071A5 (enExample) 2015-10-15

Family

ID=46888663

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014528610A Pending JP2014527071A (ja) 2011-08-31 2012-08-30 H−ホスホネートによるナノ粒子pegの改変

Country Status (9)

Country Link
US (2) US8889657B2 (enExample)
EP (1) EP2750712A2 (enExample)
JP (1) JP2014527071A (enExample)
KR (1) KR20140067070A (enExample)
CN (1) CN103930135A (enExample)
BR (1) BR112014004544A2 (enExample)
CA (1) CA2845845A1 (enExample)
IL (1) IL231215A0 (enExample)
WO (1) WO2013033438A2 (enExample)

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DK4108671T3 (da) 2010-10-01 2025-01-06 Modernatx Inc Modificerede nukleosider, nukleotider og nukleinsyrer samt anvendelser deraf
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
JP6113737B2 (ja) 2011-10-03 2017-04-12 モデルナティエックス インコーポレイテッドModernaTX,Inc. 修飾型のヌクレオシド、ヌクレオチドおよび核酸、ならびにそれらの使用方法
KR20140102759A (ko) 2011-12-16 2014-08-22 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
EP2834259A4 (en) 2012-04-02 2016-08-24 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
US10258698B2 (en) 2013-03-14 2019-04-16 Modernatx, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
JP6190534B2 (ja) 2013-08-22 2017-08-30 ソニー株式会社 水溶性蛍光染料又は有色染料及びその使用方法
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
EP3169693B1 (en) 2014-07-16 2022-03-09 ModernaTX, Inc. Chimeric polynucleotides
EP3171895A1 (en) 2014-07-23 2017-05-31 Modernatx, Inc. Modified polynucleotides for the production of intrabodies
EP3350157B1 (en) 2015-09-17 2022-01-05 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
WO2017067592A1 (en) 2015-10-21 2017-04-27 Biontech Ag Cytotoxic immunostimulating particles and uses thereof
CA3002922A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Human cytomegalovirus vaccine
JP6925688B2 (ja) 2015-10-22 2021-08-25 モデルナティーエックス, インコーポレイテッド 水痘帯状疱疹ウイルス(vzv)のための核酸ワクチン
CA3003103A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Broad spectrum influenza virus vaccine
BR112018008090A2 (pt) 2015-10-22 2018-11-13 Modernatx Inc vacina de vírus do herpes simplex.
JP7687767B2 (ja) 2015-10-22 2025-06-03 モデルナティエックス インコーポレイテッド 呼吸器合胞体ウイルスワクチン
MA47016A (fr) 2015-10-22 2018-08-29 Modernatx Inc Vaccins contre les virus respiratoires
ES2924407T3 (es) 2015-12-10 2022-10-06 Modernatx Inc Composiciones y procedimientos para el suministro de agentes terapéuticos
SI3394030T1 (sl) 2015-12-22 2022-04-29 Modernatx, Inc. Sestave za doziranje sredstev v celice
LT3394093T (lt) 2015-12-23 2022-04-25 Modernatx, Inc. Ox40 ligandus koduojančių polinukleotidų naudojimo būdai
EP3400023A1 (en) 2016-01-10 2018-11-14 ModernaTX, Inc. Therapeutic mrnas encoding anti ctla-4 antibodies
AU2017240154B2 (en) 2016-04-01 2021-08-12 Sony Group Corporation Ultra bright dimeric or polymeric dyes
EP3440136B1 (en) 2016-04-06 2025-07-23 Sony Group Corporation Ultra bright dimeric or polymeric dyes with spacing linker groups
US11685835B2 (en) 2016-05-11 2023-06-27 Sony Corporation Ultra bright dimeric or polymeric dyes
JP7312929B2 (ja) 2016-07-29 2023-07-24 ソニーグループ株式会社 超明色二量体またはポリマー色素およびその調製のための方法
US10072032B2 (en) * 2016-09-19 2018-09-11 Afton Chemical Corporation AminoBisPhosphonate antiwear additives
US11583504B2 (en) 2016-11-08 2023-02-21 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
ES2911186T3 (es) 2017-03-15 2022-05-18 Modernatx Inc Formas cristalinas de aminolípidos
FI3596041T3 (fi) 2017-03-15 2023-01-31 Yhdiste ja koostumuksia terapeuttisten aineiden antamiseen solun sisään
JP7332478B2 (ja) 2017-03-15 2023-08-23 モデルナティエックス インコーポレイテッド 脂質ナノ粒子製剤
US11485972B2 (en) 2017-05-18 2022-11-01 Modernatx, Inc. Modified messenger RNA comprising functional RNA elements
US11421011B2 (en) 2017-05-18 2022-08-23 Modernatx, Inc. Polynucleotides encoding tethered interleukin-12 (IL12) polypeptides and uses thereof
EP3638292A1 (en) 2017-06-14 2020-04-22 ModernaTX, Inc. Polynucleotides encoding coagulation factor viii
EP3638678B1 (en) 2017-06-14 2025-12-03 ModernaTX, Inc. Compounds and compositions for intracellular delivery of agents
US11786607B2 (en) 2017-06-15 2023-10-17 Modernatx, Inc. RNA formulations
AU2018326799A1 (en) 2017-08-31 2020-02-27 Modernatx, Inc. Methods of making lipid nanoparticles
EP3691689A1 (en) * 2017-10-05 2020-08-12 Sony Corporation Programmable dendritic drugs
CN111315415A (zh) 2017-10-05 2020-06-19 索尼公司 可编程的聚合药物
WO2019099789A1 (en) 2017-11-16 2019-05-23 Sony Corporation Programmable polymeric drugs
WO2019104195A1 (en) 2017-11-22 2019-05-31 Modernatx, Inc. Polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits for the treatment of propionic acidemia
US11939601B2 (en) 2017-11-22 2024-03-26 Modernatx, Inc. Polynucleotides encoding phenylalanine hydroxylase for the treatment of phenylketonuria
JP7423522B2 (ja) 2017-11-22 2024-01-29 モダーナティエックス・インコーポレイテッド 尿素サイクル異常症の治療のためのオルニチントランスカルバミラーゼをコードするポリヌクレオチド
US11802146B2 (en) 2018-01-05 2023-10-31 Modernatx, Inc. Polynucleotides encoding anti-chikungunya virus antibodies
JP7813098B2 (ja) 2018-01-12 2026-02-12 ソニーグループ株式会社 生物学的に活性な化合物を含む剛性間隔基を有するポリマー
JP2021510698A (ja) 2018-01-12 2021-04-30 ソニー株式会社 生物学的に活性な化合物を含むホスホアルキルリボースポリマー
EP3737419B1 (en) 2018-01-12 2024-04-10 Sony Group Corporation Phosphoalkyl polymers comprising biologically active compounds
US20190262793A1 (en) * 2018-02-28 2019-08-29 Southwest Research Institute Polymer-Encapsulated Polyhemoglobin-Based Oxygen Carrier
CN112041680A (zh) 2018-03-19 2020-12-04 索尼公司 二价金属用于增强荧光信号的应用
EP3768689A1 (en) 2018-03-21 2021-01-27 Sony Corporation Polymeric tandem dyes with linker groups
EP3773745A1 (en) 2018-04-11 2021-02-17 ModernaTX, Inc. Messenger rna comprising functional rna elements
WO2019226650A1 (en) 2018-05-23 2019-11-28 Modernatx, Inc. Delivery of dna
CN112313242A (zh) 2018-06-27 2021-02-02 索尼公司 具有含脱氧核糖的连接体基团的聚合物染料
KR20210032434A (ko) 2018-07-13 2021-03-24 소니 주식회사 유기인산염 단위를 포함하는 백본을 갖는 중합체성 염료
US20220184185A1 (en) 2018-07-25 2022-06-16 Modernatx, Inc. Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
MA53545A (fr) 2018-09-02 2021-07-14 Modernatx Inc Polynucléotides codant pour l'acyl-coa déshydrogénase à très longue chaîne pour le traitement de l'insuffisance en acyl-coa déshydrogénase à très longue chaîne
US20220054610A1 (en) 2018-09-12 2022-02-24 University Of Florida Research Foundation, Inc. Slow-cycling cell-rna based nanoparticle vaccine to treat cancer
MX2021003015A (es) 2018-09-13 2021-07-15 Modernatx Inc Polinucleotidos que codifican glucosa-6-fosfatasa para el tratamiento de la glucogenosis.
EP3849594A2 (en) 2018-09-13 2021-07-21 Modernatx, Inc. Polynucleotides encoding branched-chain alpha-ketoacid dehydrogenase complex e1-alpha, e1-beta, and e2 subunits for the treatment of maple syrup urine disease
AU2019339430A1 (en) 2018-09-14 2021-04-29 Modernatx, Inc. Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide A1 for the treatment of Crigler-Najjar Syndrome
EP3853202A1 (en) 2018-09-19 2021-07-28 ModernaTX, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
EP4509118A3 (en) 2018-09-19 2025-05-14 ModernaTX, Inc. High-purity peg lipids and uses thereof
WO2020061284A1 (en) 2018-09-19 2020-03-26 Modernatx, Inc. Peg lipids and uses thereof
US12090235B2 (en) 2018-09-20 2024-09-17 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
MA53734A (fr) 2018-09-27 2021-08-04 Modernatx Inc Polynucléotides codant pour l'arginase 1 pour le traitement d'une déficience en arginase
BR112021006167A8 (pt) * 2018-10-01 2022-10-18 Univ Mainz Johannes Gutenberg Partículas de rna compreendendo polisarcosina
WO2020069718A1 (en) * 2018-10-01 2020-04-09 Johannes Gutenberg-Universität Mainz Rna particles comprising polysarcosine
WO2020097409A2 (en) 2018-11-08 2020-05-14 Modernatx, Inc. Use of mrna encoding ox40l to treat cancer in human patients
KR102136657B1 (ko) * 2018-12-24 2020-07-22 연세대학교 산학협력단 야누스 펩타이드 덴드리머 및 이의 용도
US12558407B2 (en) 2019-05-02 2026-02-24 University Of Florida Research Foundation, Inc. Compositions for treatment of diffuse intrinsic pontine glioma
JP2022532078A (ja) 2019-05-08 2022-07-13 アストラゼネカ アクチボラグ 皮膚及び創傷のための組成物並びにその使用の方法
US20220370354A1 (en) 2019-05-08 2022-11-24 Modernatx, Inc. Polynucleotides encoding methylmalonyl-coa mutase for the treatment of methylmalonic acidemia
MA56539A (fr) 2019-06-24 2022-04-27 Modernatx Inc Arn messager résistant à l'endonucléase et utilisations correspondantes
US20220387628A1 (en) 2019-06-24 2022-12-08 Modernatx, Inc. Messenger rna comprising functional rna elements and uses thereof
BR112022004759A2 (pt) 2019-09-19 2022-06-21 Modernatx Inc Composições e compostos lipídicos com cauda ramificada para entrega intracelular de agentes terapêuticos
CN113383043A (zh) 2019-09-26 2021-09-10 索尼集团公司 具有连接体基团的聚合物串联染料
US20230235298A1 (en) 2020-06-01 2023-07-27 Modernatx, Inc. Phenylalanine hydroxylase variants and uses thereof
WO2021252354A1 (en) 2020-06-12 2021-12-16 University Of Rochester ENCODING AND EXPRESSION OF ACE-tRNAs
US20230406895A1 (en) 2020-11-13 2023-12-21 Modernatx, Inc. Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
JP2023552448A (ja) 2020-12-07 2023-12-15 ソニーグループ株式会社 二量体色素又はポリマー色素における輝度を増強するためのスペーシングリンカー基の設計
US11524023B2 (en) 2021-02-19 2022-12-13 Modernatx, Inc. Lipid nanoparticle compositions and methods of formulating the same
WO2022204390A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding phenylalanine hydroxylase and uses thereof
WO2022204371A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding glucose-6-phosphatase and uses thereof
US20240216288A1 (en) 2021-03-24 2024-07-04 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits and uses thereof
US20240226025A1 (en) 2021-03-24 2024-07-11 Modernatx, Inc. Polynucleotides encoding methylmalonyl-coa mutase for the treatment of methylmalonic acidemia
US20240189449A1 (en) 2021-03-24 2024-06-13 Modernatx, Inc. Lipid nanoparticles and polynucleotides encoding ornithine transcarbamylase for the treatment of ornithine transcarbamylase deficiency
WO2022266083A2 (en) 2021-06-15 2022-12-22 Modernatx, Inc. Engineered polynucleotides for cell-type or microenvironment-specific expression
US20240376445A1 (en) 2021-06-22 2024-11-14 Modernatx, Inc. Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome
US20250017867A1 (en) 2021-10-01 2025-01-16 Modernatx, Inc. Polynucleotides encoding relaxin for the treatment of fibrosis and/or cardiovascular disease
AU2023215397A1 (en) 2022-02-07 2024-08-22 University Of Rochester Optimized sequences for enhanced trna expression or/and nonsense mutation suppression.
EP4482962A1 (en) 2022-02-24 2025-01-01 IO Biotech ApS Nucleotide delivery of cancer therapy
WO2023177904A1 (en) 2022-03-18 2023-09-21 Modernatx, Inc. Sterile filtration of lipid nanoparticles and filtration analysis thereof for biological applications
EP4499153A2 (en) 2022-03-25 2025-02-05 ModernaTX, Inc. Polynucleotides encoding fanconi anemia, complementation group proteins for the treatment of fanconi anemia
WO2023196399A1 (en) 2022-04-06 2023-10-12 Modernatx, Inc. Lipid nanoparticles and polynucleotides encoding argininosuccinate lyase for the treatment of argininosuccinic aciduria
WO2023215498A2 (en) 2022-05-05 2023-11-09 Modernatx, Inc. Compositions and methods for cd28 antagonism
CA3257557A1 (en) 2022-06-02 2023-12-07 Mitsubishi Chemical Corporation HIGH-PURITY ALKYLETAIN COMPOUNDS AND THEIR MANUFACTURING PROCESSES
MA71619A (fr) 2022-07-26 2025-05-30 Modernatx, Inc. Polynucléotides modifiés pour la régulation temporelle de l'expression
US20260069712A1 (en) 2022-08-23 2026-03-12 Modernatx, Inc. Methods for purification of ionizable lipids
WO2024097639A1 (en) 2022-10-31 2024-05-10 Modernatx, Inc. Hsa-binding antibodies and binding proteins and uses thereof
WO2024118866A1 (en) 2022-12-01 2024-06-06 Modernatx, Inc. Gpc3-specific antibodies, binding domains, and related proteins and uses thereof
WO2024197033A1 (en) 2023-03-21 2024-09-26 Modernatx, Inc. Polynucleotides encoding relaxin for the treatment of heart failure
WO2024229321A1 (en) 2023-05-03 2024-11-07 Modernatx, Inc. Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
EP4520345A1 (en) 2023-09-06 2025-03-12 Myneo Nv Product
WO2025072482A1 (en) 2023-09-27 2025-04-03 Modernatx, Inc. Immunoglobulin a protease polypeptides, polynucleotides, and uses thereof
WO2025101685A1 (en) 2023-11-09 2025-05-15 University Of Rochester Suppression of nonsense mutations using anticodon engineered (ace)-trnas
WO2025255199A1 (en) 2024-06-05 2025-12-11 Modernatx, Inc. Argininosuccinate synthase 1 and argininosuccinate lyase polypeptides and polynucleotides and uses thereof
WO2026030209A1 (en) 2024-07-29 2026-02-05 University Of Rochester Use of decoding trnas to boost protein expression or function

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE514095C (de) * 1927-07-24 1930-12-11 Knoll Akt Ges Chemische Fabrik Verfahren zur Herstellung von Estern der Sterine mit Sauerstoffsaeuren des Phosphors
CH336065A (de) * 1954-03-05 1959-02-15 Ciba Geigy Verfahren zur Herstellung von neuen Stickstoff und Phosphor enthaltenden Verbindungen
GB1128086A (en) * 1966-10-27 1968-09-25 Pure Chem Ltd Improvements relating to hydroxy-containing phosphonates and polyurethanes
US3974209A (en) * 1971-08-04 1976-08-10 Monsanto Company Substituted tertiary amines and processes for preparing the same
DE3202127A1 (de) * 1982-01-23 1983-07-28 Agfa-Gevaert Ag, 5090 Leverkusen Fotografisches material mit einer durch organische farbstoffe anfaerbbaren schicht
US4568432A (en) 1984-12-28 1986-02-04 Monsanto Company Process for preparing glyphosate and glyphosate derivatives
EP0209848A3 (en) * 1985-07-24 1988-07-27 Merck & Co. Inc. Enzyme inhibitors
US5567588A (en) 1990-06-11 1996-10-22 University Research Corporation Systematic evolution of ligands by exponential enrichment: Solution SELEX
DE4408729A1 (de) * 1994-03-15 1995-09-21 Hoechst Ag Nichtcyclische Chelatbildner auf Basis von Aminodialkylphosphoroxiden zur Herstellung von Technetium- oder Rheniumkomplexen
US6054608A (en) 1997-05-05 2000-04-25 Monsanto Company Method for preparing formylphosphonic acid
ZA989394B (en) * 1997-10-15 1999-04-15 Monsanto Co Selective functionalization of sodium glycinate
JP3799435B2 (ja) * 1998-04-13 2006-07-19 三共有機合成株式会社 安定化された抗菌性樹脂組成物
US7833992B2 (en) * 2001-05-18 2010-11-16 Merck Sharpe & Dohme Conjugates and compositions for cellular delivery
DE10049074A1 (de) 2000-10-02 2002-04-18 Andreas Kage Verfahren zur Selektion hochaffin an ein Target bindender Nukleinsäuren
AU2002249935A1 (en) * 2001-01-08 2002-08-19 Neorx Corporation Radioactively labelled conjugates of phosphonates
DE10259935A1 (de) * 2002-12-20 2004-07-01 Bayer Ag Herstellung und Verwendung von in-situ-modifizierten Nanopartikeln
US20040198783A1 (en) * 2003-04-03 2004-10-07 Semafore Pharmaceuticals Inc. Targeted bone marrow protection agents
JP2006523237A (ja) * 2003-04-03 2006-10-12 セマフォア ファーマシューティカルズ, インコーポレイテッド Pi−3キナーゼインヒビタープロドラッグ
JP2010535701A (ja) * 2003-04-25 2010-11-25 ギリアード サイエンシーズ, インコーポレイテッド 抗癌ホスホネートアナログ
DE10320071A1 (de) * 2003-05-05 2004-12-02 Basf Ag Alkoxygruppen aufweisende Ester von Phosphor-Sauerstoff-Säuren und ihre Verwendung als Korrosionsinhibitoren
US7420000B2 (en) * 2003-09-10 2008-09-02 University Of Southern California Amino phosphonate and amino bis-phosphonate derivatives
DE102004032781A1 (de) * 2004-01-23 2005-08-11 Mcs Micro Carrier Systems Gmbh Bisphosphonsäurederivate
WO2006078646A2 (en) 2005-01-18 2006-07-27 Caltagirone Gaetano T A class of supramolecular drug molecules and methods of identification and use thereof
US20090123507A1 (en) * 2005-03-08 2009-05-14 Reinhold Ohrlein Metal Oxide Nanoparticles Coated With Specific N-Acylaminomethylene Phosphonates
WO2009066513A1 (ja) * 2007-11-19 2009-05-28 The University Of Tokyo 標的核酸を位置選択的に切断する方法
US20100173871A1 (en) * 2008-08-01 2010-07-08 Centre National De La Recherche Scientifique Phosphorylated dendrimers as antiinflammatory drugs
DK2355851T3 (en) * 2008-11-10 2018-06-25 Arbutus Biopharma Corp Newly known lipids and compositions for release of therapeutic agents
JP5381269B2 (ja) * 2009-04-15 2014-01-08 コニカミノルタ株式会社 光学フィルム、光学フィルムの製造方法、偏光板及び液晶表示装置
EP2533764A4 (en) * 2010-02-08 2016-08-31 Univ Nebraska BIOMINERAL AND METAL BINDING LIPOSOME, THEIR SYNTHESIS AND METHOD FOR THE PRODUCTION THEREOF
AU2011217142A1 (en) * 2010-02-18 2012-09-06 Hospital General Universitario Gregorio Maranon (Hgugm) Carbosilane dendrimers and the use thereof as antiviral agents
JO3131B1 (ar) 2010-04-27 2017-09-20 Glaxosmithkline Llc مركبات كيميائية
CN102093421B (zh) * 2011-01-28 2014-07-02 北京康辰药业有限公司 一种含磷取代基的喹啉类化合物及其制备方法、以及含有该化合物的药物组合物及其应用

Similar Documents

Publication Publication Date Title
JP2014527071A5 (enExample)
Jadon et al. Docetaxel-loaded lipid-polymer hybrid nanoparticles for breast cancer therapeutics
Wang et al. Diagnostic imaging and therapeutic application of nanoparticles targeting the liver
Peng et al. Targeted delivery of cisplatin to lung cancer using ScFvEGFR-heparin-cisplatin nanoparticles
CN102858367B (zh) 抗原或药物递送复合物
Cobaleda‐Siles et al. An iron oxide nanocarrier for dsRNA to target lymph nodes and strongly activate cells of the immune system
Mekuria et al. PAMAM dendrimer based targeted nano-carrier for bio-imaging and therapeutic agents
CN104582732A (zh) 治疗癌症的组合物及其制造方法
JP2013538829A5 (enExample)
US20200009050A1 (en) Pharmaceutical composition, preparation and uses thereof
JP2014527071A (ja) H−ホスホネートによるナノ粒子pegの改変
US10434194B2 (en) PSMA targeted nanobubbles for diagnostic and therapeutic applications
RU2012124266A (ru) Хелаты марганца и их применение в качестве контрастных агентов в магнитно-резонансной визуализации (mpb)
JP2013505204A (ja) sPLA2加水分解性リポソームの医学的使用
CA2968473A1 (en) Pharmaceutical composition, preparation and uses thereof
US12410448B2 (en) Nanoparticle compositions containing sugar functionalized nucleic acid carriers
JP2016094425A5 (enExample)
JP2015502946A5 (enExample)
Zoulikha et al. Targeted Drug Delivery for Chronic Lymphocytic Leukemia: Zoulikha and He
Tang et al. Nanovector assembled from natural egg yolk lipids for tumor-targeted delivery of therapeutics
JP2014525459A5 (enExample)
Majee et al. Harnessing nanotheranostics for the management of breast and ovarian cancer
JP7179154B2 (ja) ウイルス送達用ポリマーナノ粒子組成物及びその製造方法
US20170266325A1 (en) Compositions for nanoconfinement induced contrast enhancement and methods of making and using thereof
CA3157379A1 (en) Delivery system complexes comprising a precipitate of an active agent and methods of use